136 related articles for article (PubMed ID: 21819452)
1. Biomarkers for skin involvement and fibrotic activity in scleroderma.
Moinzadeh P; Denton CP; Abraham D; Ong V; Hunzelmann N; Eckes B; Krieg T
J Eur Acad Dermatol Venereol; 2012 Mar; 26(3):267-76. PubMed ID: 21819452
[TBL] [Abstract][Full Text] [Related]
2. Update on biomarkers in systemic sclerosis: tools for diagnosis and treatment.
Affandi AJ; Radstake TR; Marut W
Semin Immunopathol; 2015 Sep; 37(5):475-87. PubMed ID: 26168983
[TBL] [Abstract][Full Text] [Related]
3. COMP: a candidate molecule in the pathogenesis of systemic sclerosis with a potential as a disease marker.
Hesselstrand R; Kassner A; Heinegård D; Saxne T
Ann Rheum Dis; 2008 Sep; 67(9):1242-8. PubMed ID: 18065498
[TBL] [Abstract][Full Text] [Related]
4. Increased serum levels and tissue expression of matrix metalloproteinase-12 in patients with systemic sclerosis: correlation with severity of skin and pulmonary fibrosis and vascular damage.
Manetti M; Guiducci S; Romano E; Bellando-Randone S; Conforti ML; Ibba-Manneschi L; Matucci-Cerinic M
Ann Rheum Dis; 2012 Jun; 71(6):1064-72. PubMed ID: 22258486
[TBL] [Abstract][Full Text] [Related]
5. The Modified Hand Mobility in Scleroderma Test and Skin Involvement - A Followup Study.
Sandqvist G; Wuttge DM; Hesselstrand R
J Rheumatol; 2016 Jul; 43(7):1356-62. PubMed ID: 27134250
[TBL] [Abstract][Full Text] [Related]
6. Skin involvement in scleroderma--where histological and clinical scores meet.
Verrecchia F; Laboureau J; Verola O; Roos N; Porcher R; Bruneval P; Ertault M; Tiev K; Michel L; Mauviel A; Farge D
Rheumatology (Oxford); 2007 May; 46(5):833-41. PubMed ID: 17255134
[TBL] [Abstract][Full Text] [Related]
7. [Systemic sclerosis and scleroderma circumscripta--disturbances of selected serum parameters which are responsible for vascular changes and CD34 expression in involved skin].
Dziankowska-Bartkowiak B; Zebrowska A; Wagrowska-Danielewicz M; Kobos J; Waszczykowska E
Przegl Lek; 2009; 66(12):1040-5. PubMed ID: 20514902
[TBL] [Abstract][Full Text] [Related]
8. Serum periostin levels are correlated with progressive skin sclerosis in patients with systemic sclerosis.
Yamaguchi Y; Ono J; Masuoka M; Ohta S; Izuhara K; Ikezawa Z; Aihara M; Takahashi K
Br J Dermatol; 2013 Apr; 168(4):717-25. PubMed ID: 23110679
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of skin fibrosis in systemic sclerosis.
Jinnin M
J Dermatol; 2010 Jan; 37(1):11-25. PubMed ID: 20175837
[TBL] [Abstract][Full Text] [Related]
10. Skin sclerosis is only of limited value to identify SSc patients with severe manifestations--an analysis of a distinct patient subgroup of the German Systemic Sclerosis Network (DNSS) Register.
Hanitsch LG; Burmester GR; Witt C; Hunzelmann N; Genth E; Krieg T; Lehmacher W; Melchers I; Meurer M; Müller-Ladner U; Schulze-Lohoff E; Becker M; Sunderkoetter C; ; Riemekasten G
Rheumatology (Oxford); 2009 Jan; 48(1):70-3. PubMed ID: 19056798
[TBL] [Abstract][Full Text] [Related]
11. Monocyte chemoattractant protein 3 as a mediator of fibrosis: Overexpression in systemic sclerosis and the type 1 tight-skin mouse.
Ong VH; Evans LA; Shiwen X; Fisher IB; Rajkumar V; Abraham DJ; Black CM; Denton CP
Arthritis Rheum; 2003 Jul; 48(7):1979-91. PubMed ID: 12847692
[TBL] [Abstract][Full Text] [Related]
12. Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts.
Wang Y; Fan PS; Kahaleh B
Arthritis Rheum; 2006 Jul; 54(7):2271-9. PubMed ID: 16802366
[TBL] [Abstract][Full Text] [Related]
13. Circulating endothelin-1 levels in systemic sclerosis subsets--a marker of fibrosis or vascular dysfunction?
Vancheeswaran R; Magoulas T; Efrat G; Wheeler-Jones C; Olsen I; Penny R; Black CM
J Rheumatol; 1994 Oct; 21(10):1838-44. PubMed ID: 7837147
[TBL] [Abstract][Full Text] [Related]
14. Abnormal collagen V deposition in dermis correlates with skin thickening and disease activity in systemic sclerosis.
Martin P; Teodoro WR; Velosa AP; de Morais J; Carrasco S; Christmann RB; Goldenstein-Schainberg C; Parra ER; Katayama ML; Sotto MN; Capelozzi VL; Yoshinari NH
Autoimmun Rev; 2012 Sep; 11(11):827-35. PubMed ID: 22406224
[TBL] [Abstract][Full Text] [Related]
15. Serum levels of galectin-3: possible association with fibrosis, aberrant angiogenesis, and immune activation in patients with systemic sclerosis.
Taniguchi T; Asano Y; Akamata K; Noda S; Masui Y; Yamada D; Takahashi T; Ichimura Y; Toyama T; Tamaki Z; Tada Y; Sugaya M; Kadono T; Sato S
J Rheumatol; 2012 Mar; 39(3):539-44. PubMed ID: 22247367
[TBL] [Abstract][Full Text] [Related]
16. Correlation of serum collagen I carboxyterminal telopeptide concentrations with cutaneous and pulmonary involvement in systemic sclerosis.
Allanore Y; Borderie D; Lemaréchal H; Cherruau B; Ekindjian OG; Kahan A
J Rheumatol; 2003 Jan; 30(1):68-73. PubMed ID: 12508392
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis.
Matsushita T; Hasegawa M; Hamaguchi Y; Takehara K; Sato S
J Rheumatol; 2006 Feb; 33(2):275-84. PubMed ID: 16465658
[TBL] [Abstract][Full Text] [Related]
18. Emerging diagnostic and therapeutic challenges for skin fibrosis in systemic sclerosis.
Abraham D; Lescoat A; Stratton R
Mol Aspects Med; 2024 Apr; 96():101252. PubMed ID: 38325132
[TBL] [Abstract][Full Text] [Related]
19. CD109 overexpression ameliorates skin fibrosis in a mouse model of bleomycin-induced scleroderma.
Vorstenbosch J; Al-Ajmi H; Winocour S; Trzeciak A; Lessard L; Philip A
Arthritis Rheum; 2013 May; 65(5):1378-83. PubMed ID: 23436317
[TBL] [Abstract][Full Text] [Related]
20. Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group.
Muangchan C; Harding S; Khimdas S; Bonner A; ; Baron M; Pope J
Arthritis Care Res (Hoboken); 2012 Sep; 64(9):1405-14. PubMed ID: 22556030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
